SYNGAP1 mutations account for an estimated 1% of total nonsyndromic ID cases (Hamdan et al., 2009; Gamache et al., 2020) and there is currently no targeted treatment for SYNGAP1-related NDD. Here, SYNGAP1 is linked to Neurodevelopmental delay.